Teacher Retirement System of Texas boosted its stake in ABIOMED, Inc. (NASDAQ:ABMD) by 319.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,424 shares of the medical equipment provider’s stock after purchasing an additional 10,989 shares during the period. Teacher Retirement System of Texas’ holdings in ABIOMED were worth $2,703,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in the business. Janus Henderson Group PLC grew its position in shares of ABIOMED by 102.0% in the 3rd quarter. Janus Henderson Group PLC now owns 1,076,829 shares of the medical equipment provider’s stock worth $181,553,000 after buying an additional 543,793 shares during the last quarter. American Century Companies Inc. grew its position in shares of ABIOMED by 99.0% in the 4th quarter. American Century Companies Inc. now owns 963,517 shares of the medical equipment provider’s stock worth $180,573,000 after buying an additional 479,375 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of ABIOMED by 2,219.4% in the 3rd quarter. Wells Fargo & Company MN now owns 364,427 shares of the medical equipment provider’s stock worth $61,443,000 after buying an additional 348,715 shares during the last quarter. Atlantic Trust Group LLC bought a new stake in shares of ABIOMED in the 3rd quarter worth approximately $18,240,000. Finally, Strs Ohio grew its position in shares of ABIOMED by 309.8% in the 3rd quarter. Strs Ohio now owns 142,879 shares of the medical equipment provider’s stock worth $24,089,000 after buying an additional 108,012 shares during the last quarter. 86.99% of the stock is currently owned by institutional investors and hedge funds.
Several research firms recently weighed in on ABMD. SunTrust Banks restated a “buy” rating and set a $370.00 price target on shares of ABIOMED in a research report on Friday, February 16th. Leerink Swann lifted their price target on ABIOMED to $300.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Zacks Investment Research lowered ABIOMED from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 6th. BTIG Research restated a “hold” rating on shares of ABIOMED in a research report on Sunday, February 4th. Finally, Morgan Stanley lifted their price target on ABIOMED from $204.00 to $259.00 and gave the company an “equal weight” rating in a research report on Friday, February 2nd. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $288.86.
Shares of ABIOMED, Inc. (ABMD) opened at $270.48 on Wednesday. The firm has a market capitalization of $11,854.94, a P/E ratio of 139.45, a P/E/G ratio of 3.55 and a beta of 0.36. ABIOMED, Inc. has a 1 year low of $114.28 and a 1 year high of $273.27.
ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.20. The business had revenue of $154.00 million during the quarter, compared to analysts’ expectations of $154.00 million. ABIOMED had a return on equity of 15.54% and a net margin of 16.58%. The firm’s quarterly revenue was up 34.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.34 earnings per share. equities analysts forecast that ABIOMED, Inc. will post 2.39 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.thelincolnianonline.com/2018/02/21/teacher-retirement-system-of-texas-has-2-70-million-holdings-in-abiomed-inc-abmd.html.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.